IgG stimulated remyelination of peripheral nerves

US8986670B2 · kind B2 · utility

Assignees

• Baxter International Inc. · US
• Baxter Healthcare SA · CH

Inventors

• Patrick Küry · Langendorf, CH
• Nevena Tzekova · Düsseldorf, DE
• Hans-Peter Hartung · Düsseldorf, DE
• Corinna Hermann · Wien, AT
• Birgit Maria Reipert · Deutsch-Wagram, AT
• Hans-Peter Schwarz · Wien, AT
• Hartmut Ehrlich · Paris, FR
• Sebastian BUNK · Wien, AT

Key dates

• Filing date: Feb 28, 2013
• Grant date: Mar 24, 2015
• Expiry date: Feb 28, 2033

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.